Form 4: Bicycle Therapeutics Executive Granted Stock Options

Michael Charles Ferguson Hannay, Chief Product & Supply Chain Officer at Bicycle Therapeutics, was granted stock options for 58,000 ordinary shares on March 19, 2024.

Summary

• Michael Charles Ferguson Hannay, Chief Product & Supply Chain Officer of Bicycle Therapeutics plc, was granted employee stock options on March 19, 2024.
• The options grant covers 58,000 ordinary shares at an exercise price of $24.12.
• The options vest over a four-year period, with one-fourth vesting on March 19, 2025, and the remaining shares vesting in 36 equal monthly installments thereafter.
• Following the transaction, Hannay directly owns options for 58,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a standard executive compensation practice, indicating confidence in the company's future.

Positives

• The granting of stock options to a key executive aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. The size and vesting schedule of the grant are typical for executive compensation packages in similar companies.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
• Companies like Amgen, Gilead, and Biogen routinely use stock options to incentivize their leadership teams.
• The vesting schedule of four years with a one-year cliff is also a common practice to ensure long-term commitment.

Stakeholder Impact

• Shareholders may view the option grant as a positive sign, aligning executive interests with company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates